Contrasting Predictive Technology Group (OTCMKTS:PRED) & Galapagos (NASDAQ:GLPG)

Share on StockTwits

Predictive Technology Group (OTCMKTS:PRED) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Predictive Technology Group and Galapagos, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Predictive Technology Group 0 0 0 0 N/A
Galapagos 3 9 5 0 2.12

Galapagos has a consensus target price of $181.08, suggesting a potential upside of 80.16%. Given Galapagos’ higher probable upside, analysts clearly believe Galapagos is more favorable than Predictive Technology Group.

Risk and Volatility

Predictive Technology Group has a beta of -0.54, suggesting that its share price is 154% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.


This table compares Predictive Technology Group and Galapagos’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Predictive Technology Group -157.71% -54.66% -42.44%
Galapagos -70.67% -11.78% -5.58%

Earnings and Valuation

This table compares Predictive Technology Group and Galapagos’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Predictive Technology Group $43.49 million 0.83 -$15.31 million ($0.06) -2.00
Galapagos $1.00 billion 6.55 $167.83 million $5.46 18.41

Galapagos has higher revenue and earnings than Predictive Technology Group. Predictive Technology Group is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

11.1% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Galapagos beats Predictive Technology Group on 12 of the 13 factors compared between the two stocks.

About Predictive Technology Group

Predictive Technology Group, Inc., together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic, therapeutic, and human cellular and tissue-based products (HCT/Ps). It operates in two segments, Human Cellular and Tissues Products (HCT/Ps); and Diagnostics and Therapeutics. The company provides FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women experiencing infertility because of endometriosis and other genetic conditions; and regenerative medicine products, including AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte for use in regenerative medicine applications. It has a collaboration agreement with Atrin Pharmaceuticals LLC to develop molecular diagnostic tools to facilitate enhanced selection of cancer patients. The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah.

About Galapagos

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Receive News & Ratings for Predictive Technology Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Predictive Technology Group and related companies with's FREE daily email newsletter.